Splash
Verona Pharma

Breathtaking Science

Verona Pharma is developing life enhancing treatments for respiratory diseases.
Splash
Verona Pharma Reports Positive Efficacy and Safety Data with Single Dose pMDI Formulation of Ensifentrine in COPD

Statistically significant and clinically meaningful improvements in lung function Ensifentrine has now demonstrated positive efficacy and safety in COPD patients via three widely used inhalation modes: nebulizer, DPI and pMDI Initiation of multiple dose part of pMDI trial postponed due to the

We’re a clinical‑stage biopharmaceutical company focused on developing and commercializing innovative prescription medicines.

We are focused on treating respiratory diseases with significant unmet medical needs, such as COPD, cystic fibrosis and asthma. The Company is listed on the Nasdaq Global Market in the United States under the VRNA ticker and on the London Stock Exchange in the United Kingdom under the VRP ticker.

COPD
The unmet need

COPD

Cystic Fibrosis

Asthma

Chronic Obstructive Pulmonary Disease is a progressive respiratory disease without a cure.

The condition causes loss of lung function, hospitalisations and death. COPD affects approximately 384 million people worldwide. It is projected to be the third leading cause of death by 2030, according to the World Health Organization.

Find out more

Latest Film

Verona Pharma's novel COPD candidate "has the potential to significantly benefit patients," believes CMO Dr Kathleen Rickard

The Company expects to hold an End-of-Phase 2 meeting with the US FDA in the second quarter and anticipates starting Phase 3 later this year.

Play

Splash

© Verona Pharma plc 2020. All rights reserved